Welcome to our dedicated page for Statera Biopharma news (Ticker: STAB), a resource for investors and traders seeking the latest updates and insights on Statera Biopharma stock.
Statera Biopharma, Inc. (STAB) appears in news coverage as a clinical-stage biopharmaceutical company focused on immunotherapies that target autoimmune diseases, neutropenia/anemia, emerging viruses, and cancers. Its disclosures emphasize a proprietary platform of toll-like receptor (TLR) drugs designed to rebalance the body's immune system and restore homeostasis, which shapes the types of developments reported in STAB-related news.
News items about Statera Biopharma frequently highlight progress and challenges in its clinical and corporate trajectory. On the scientific side, releases describe programs such as STAT-201 for Crohn's disease, hematology applications involving Entolimod and STAT-600/Entolimod, STAT-401 for pancreatic cancer, STAT-300 series candidates for multiple cancers and inflammation, and STAT-205 for COVID-19, along with potential expansion into other autoimmune and inflammatory conditions.
Another recurring theme in STAB news is the company's TLR5 agonist program. A Business Wire announcement reported that Tivic Health Systems, Inc. acquired worldwide exclusive license rights from Statera Biopharma to the late-stage TLR5 agonist Entolimod for acute radiation syndrome, with options on additional indications and a derivative, Entalasta. That coverage also noted FDA Fast Track and Orphan Drug designations for Entolimod in radiation-related indications and described the transfer of certain Statera team members to Tivic Health.
Corporate and capital markets updates are also prominent in Statera Biopharma news. Releases have addressed Nasdaq listing determinations, notices of filing delinquency, the completion and filing of Form 10-K and Form 10-Q reports, and efforts to move from OTC Pink Sheets to the OTCQB Venture Marketplace. Additional items include financing-related agreements and the appointment of an independent registered public accounting firm.
Strategic collaboration announcements, such as a binding Memorandum of Understanding with Holobeam Technologies for access to holographic diagnostic imaging and therapeutic technology, and a non-binding letter of intent for a proposed merger with Worksite Labs, further contribute to the news flow. Investors and observers following STAB news can review these updates to understand how Statera Biopharma's immunotherapy platform, licensing arrangements, regulatory status, and potential transactions evolve over time.
Statera Biopharma (Nasdaq: STAB) announced it received a letter from Nasdaq on May 18, 2022, for failing to file its quarterly report on Form 10-Q by May 15, 2022. The company is currently seeking a new independent registered public accounting firm and has restructured to reduce cash burn. Statera is also working on completing transactions with Coeptis Therapeutics and Immune Therapeutics to out-license assets. Statera has until June 20, 2022, to submit a compliance plan to Nasdaq, which may extend until October 17, 2022. No assurance is given that compliance can be achieved.
Statera Biopharma (Nasdaq: STAB) announced plans to acquire a licensing option for Lay Sciences' IgY products, targeting respiratory and gastrointestinal disorders. This strategic partnership aims to generate near-term revenue by licensing and commercializing current and future products. Lay Sciences will receive an upfront payment comprising equity and cash, as well as royalties and milestone payments for IgY's development in gastrointestinal and respiratory indications. The collaboration focuses on improving treatments for chronic diseases using avian antibodies.
Statera Biopharma (Nasdaq: STAB) has announced a strategic agreement with Immune Therapeutics to sell its rights to naltrexone and met-enkephalin. This deal is expected to strengthen Statera's financial position, potentially generating over $400 million in non-dilutive cash flow through an upfront payment of $2 million, stock equity, and milestone payments. The CEO highlighted that this move will support the development of new product candidates aimed at treating various immune-related diseases.
Statera Biopharma (Nasdaq: STAB) announced it is not in compliance with Nasdaq listing rules due to a delay in filing its Annual Report on Form 10-K for the fiscal year ending December 31, 2021. The company has until June 20, 2022, to submit a compliance plan. Additionally, recent board resignations have left the company with inadequate independent directors, affecting its governance structure. The resignation of its independent auditor, Tuner, Stone & Company, further complicates its financial reporting. Statera is actively seeking a new auditor while working to regain compliance.
Statera Biopharma (Nasdaq: STAB) announced a strategic agreement with Coeptis Therapeutics to sell its rights to Entolimod and related TLR5 agonists. The transaction includes a $6 million upfront payment and milestone payments based on revenue. This move aims to enhance Statera's financial position and support the development of its immunotherapy programs. The sale is contingent on finalizing a definitive agreement and satisfying certain conditions, including financing from Coeptis.
Coeptis Therapeutics has entered into a strategic agreement with Statera Biopharma to acquire its toll-like receptor 5 (TLR5) agonist platform, including the clinical-stage candidate entolimod, for $6 million. The agreement is subject to further negotiation and financing conditions. Entolimod is being developed to treat acute radiation syndrome and has shown potential in treating neutropenia and anemia in cancer patients. This acquisition is expected to enhance Coeptis' pipeline and address underserved medical needs in light of the current geopolitical climate.
Statera Biopharma (Nasdaq: STAB) has filed a Form 12b-25 with the SEC, extending the due date for its Annual Report on Form 10-K for the fiscal year ended December 31, 2021, to April 15, 2022. The delay is attributed to challenges in completing financial statements and audit processes by its independent registered public accounting firm. Consequently, the company has postponed its conference call and webcast that was intended to discuss the financial results for the full year 2021.
Statera Biopharma (Nasdaq: STAB) will host a conference call and audio webcast on March 31, 2022, at 5:30 p.m. ET to discuss its Q4 and full-year financial results for 2021. The event invites stakeholders to hear the latest updates on corporate performance. The call will be accessible via telephone and webcast, with a replay available on their website for 90 days post-event. Statera Biopharma focuses on developing innovative immunotherapies targeting various health issues, including autoimmune diseases and cancers.
Statera Biopharma, Inc. (NASDAQ: STAB) has successfully closed its public offering of 12,555,555 units, raising approximately $5.7 million before expenses. Each unit comprises one share of common stock and two warrants with differing terms—one-year at $0.45 and five-year at $0.5625 per share. The underwriters partially exercised their option to purchase additional warrants. A 45-day option for underwriters to buy up to another 1,883,333 shares at $0.43 is also included. The offering is facilitated under a previously effective shelf registration statement.
Statera Biopharma (NASDAQ: STAB) announced a public offering of approximately 10,843,721 units priced at $0.45 each, and 1,716,666 pre-funded units at $0.44, totaling about $5.7 million in gross proceeds. Each unit includes common stock and warrants with varying terms and exercise prices. Additionally, underwriters have a 45-day option to purchase up to 1,884,057 shares to cover over-allotments. The offering, set to close around March 24, 2022, is conducted under a prior SEC registration statement.